We saw the FDA approve a groundbreaking drug, companies debut new technology to help increase our awareness of dangerous ultraviolet (UV) rays and lawmakers pass indoor tanning legislation.
You may have heard about a new medication that was recently FDA approved for cutaneous squamous cell carcinoma (CSCC). Libtayo (cemiplimab-rwlc) is a type of immunotherapy called a checkpoint blockade inhibitor, and it’s the first one approved to treat certain cases of CSCC. This is exciting news, so let’s break down how this new drug works and whom it might help.
Your eyes can focus on a tiny splinter in the finger of a squirming child, a stop sign in the distance or stars blinking light-years away. You can roll your eyes, flirt with them, do a double-take and express joy or despair without words. When you think about how amazing your eyes are, wouldn’t you do anything to protect them?
Imagine visiting the dermatologist with concerns about a strange growth on your arm. You breathe a sigh of relief when your doctor tells you that the spot is an actinic keratosis (AK), meaning it isn’t malignant…for now. It may stay benign, but it could also turn into a potentially life-threatening form of skin cancer.
Each year, we award several grants to dermatology residents, fellows and young faculty to fund research and clinical studies related to skin cancer. This year, the Todd Nagel Memorial Award was given to Dr. William Damsky, researcher at Yale University, for his study “Elucidating and Overcoming Mechanisms of Immunotherapy Resistance in Melanoma.”
With the recent FDA approval of the drug nivolumab (Opdivo®, previously approved for stage IV melanoma) as a treatment for stage III melanoma, we have reached the next important phase in the immunotherapy revolution. It is a revolution that most of the world’s top experts believe will one day, very possibly within a decade, turn advanced (stages III and IV) melanoma into a chronic, or even curable, disease rather than a deadly one.
You might already know that catching a cancer early means a more favorable prognosis. But it can be difficult to comprehend just how big a difference early detection makes with melanoma, the most dangerous form of skin cancer. Melanoma should never be underestimated, but treating a tumor early rather than after it is allowed to progress could be lifesaving.